Researchers from the Rowan University School of Osteopathic Medicine are nearing development of a blood test that can accurately detect the presence of Alzheimer’s disease, which would give physicians an opportunity to intervene at the earliest, most treatable stage.
Researchers Close in on a Blood Test for Alzheimer’s Disease, Giving Physicians Hope for Slowing Symptoms Through Preclinical Detection
A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer’s disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer’s, in the brain, according to the results of four research trials reported recently at the Alzheimer’s Association International Conference® 2014 (AAIC® 2014) in Copenhagen.
A study of nearly 315,000 colonoscopies performed by 136 gastroenterologists found that adenoma detection rates closely tracked the future risk of colorectal cancer. The study was published April 3 in the New England Journal of Medicine.
Research being performed by Durin Technologies, Inc., exploring the development of a novel blood test for Parkinson’s disease was recently awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research.
Inventages Portfolio Company, Cognoptix, Demonstrates the Ability to Accurately Identify Alzheimer’s Disease
Inventages announces that one of its portfolio companies, Cognoptix, has demonstrated unprecedented accuracy in detecting Alzheimer’s disease. A multi-site clinical trial of the SAPPHIRE II eye test showed a sensitivity of 85% and a specificity of 95% in differentiating Alzheimer’s disease patients from healthy volunteers.